Contrasting OS Therapies (OSTX) & Its Rivals

OS Therapies (NYSE:OSTX) is one of 447 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare OS Therapies to related companies based on the strength of its valuation, institutional ownership, dividends, earnings, analyst recommendations, risk and profitability.

Profitability

This table compares OS Therapies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OS Therapies	N/A	N/A	-569.57%
OS Therapies Competitors	-2,636.47%	-415.46%	-44.42%

Insider and Institutional Ownership

39.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.8% of OS Therapies shares are owned by insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares OS Therapies and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OS Therapies	N/A	-$7.79 million	-2.07
OS Therapies Competitors	$435.24 million	-$68.31 million	-7.89

OS Therapies’ rivals have higher revenue, but lower earnings than OS Therapies. OS Therapies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and price targets for OS Therapies and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OS Therapies	0	0	3	2	3.40
OS Therapies Competitors	4775	9990	16008	364	2.38

OS Therapies presently has a consensus target price of $18.00, suggesting a potential upside of 911.24%. As a group, “Pharmaceutical preparations” companies have a potential upside of 123.74%. Given OS Therapies’ stronger consensus rating and higher probable upside, analysts plainly believe OS Therapies is more favorable than its rivals.

Summary

OS Therapies beats its rivals on 8 of the 12 factors compared.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.